Sign in
Taking people in Hong KongPhase 1

Tests RO7673396 in adults with advanced solid tumors carrying RAS mutations

Tests the drug RO7673396 in adults with advanced solid tumors that have RAS mutations.

Key facts

Who runs it
Hoffmann-La Roche
Where
Hong Kong, Hong KongSee the siteAlso in 10 other countries, 24 sites
Registry title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Status
Recruiting
Phase
Phase 1
People taking part
405 people, planned
Started
30 Apr 2025
Expected to end
25 May 2029
Type of study
Interventional, 2 groups
Treatments tested
  • RO7673396
Record updated
28 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced solid tumors that cannot be cured and that carry a RAS mutation. It tests the safety of the drug RO7673396.

Age
18 years or older
Sex
All sexes can join
Disease stage
Locally advanced, recurrent or metastatic solid tumors that cannot be cured, with disease that can be measured by RECIST v1.1
Earlier treatment
No chemotherapy, immunotherapy, biologic therapy or investigational anti-cancer drug within 4 weeks or five half-lives before starting study treatment
Biomarker or test result
Confirmed RAS mutation(s)

Main reasons for not taking part

  • Taking part in another interventional clinical trial
  • Known or active brain or spinal cord (CNS) metastases that are untreated
  • History of lung scarring or inflammation (pulmonary fibrosis, pneumonitis, ILD)
  • Bowel problems that stop the drug being absorbed (such as chronic diarrhea, short bowel syndrome, inflammatory bowel disease)
  • Major surgery within 28 days before starting study treatment

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Histologically documented, locally advanced, recurrent, or metastatic incurable solid tumors
  • Participants with measurable disease according to RECIST v1.1 assessed by the investigator
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy ≥12 weeks
  • Adequate hematologic and end-organ function
  • Confirmed presence of the RAS mutation(s)

Who cannot take part

  • Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate study treatment absorption
  • Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigational agent as anti-cancer therapy within 4 weeks or five half-lives prior to initiation of study treatment
  • Major surgical procedure within 28 days prior to initiation of study treatment, or incomplete recovery from surgery that would interfere with the determination of safety or efficacy of study treatment, or anticipation of need for a major surgical procedure during the study
  • Known hypersensitivity or medical contraindication to any component of RO7673396 formulation
  • Participants with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal (GI) surgery including gastric resection, a history of inflammatory bowel disease (IBD)
  • A history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, non-infectious ILD/pneumonitis, or current evidence of active pneumonitis or ILD on screening chest CT scan
  • Known clinically significant liver disease
  • Current participant or enrollment in another interventional clinical trial
  • Known and untreated, or active central nervous system (CNS) metastases
  • Participants who are on acid-reducing agents and unable to safely discontinue them as required in the study
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures

Where in Hong Kong

Also in 10 other countries, 24 sites

  • Prince of Wales HospitalHong Kong, Hong KongTaking people

About the trial

What the trial wants to find out

This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.

The 2 groups in the trial

  • Stage ITreatment being tested

    Participants with advanced solid tumors harboring RAS mutations will receive multiple ascending doses of RO7673396, as per a pre-defined dosing regimen until unacceptable toxicity or disease progression (PD) and/or loss of clinical benefit as determined by the investigator.

    Treatment: RO7673396

  • Stage IITreatment being tested

    Participants with advanced solid tumors harboring RAS mutations will receive RO7673396 at the dose determined in Stage 1, until unacceptable toxicity or PD and/or loss of clinical benefit as determined by the investigator.

    Treatment: RO7673396

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)
Plain-language title
Tests RO7673396 in adults with advanced solid tumors carrying RAS mutationsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 September 2026